

Supplementary Financial Data  
for the First Quarter of the Year Ending March 31, 2016

I. Consolidated Financial Highlights.....	1
II. Consolidated Statements of (Comprehensive) Income .....	2
III. Consolidated Balance Sheets .....	6
IV. Quarterly Business Results .....	8
V. Major Consolidated Subsidiaries.....	8
VI. Development Pipeline.....	9
VII. Profile of Major Products under Development .....	16

July 29, 2015

Sumitomo Dainippon Pharma Co., Ltd.

- Forecasts provided in this document are based on the management's assumptions and beliefs, made in light of information available up to the day of announcement. Actual financial results may differ materially from those presented in this document, being dependent upon a number of factors.
- All values are rounded. Therefore totals may not be consistent with aggregated figures.

## I. Consolidated Financial Highlights

### 1. Consolidated Statements of Income

(Billions of yen)

	FY2014 1Q	FY2015 1Q	Change (%)	FY2015 Apr.-Sep. (Forecast)		Change (%)	FY2015 (Forecast)		Change (%)
Net sales	89.7	98.1	9.3	[193.0]	197.5	10.8	[392.0]	401.0	8.0
Cost of sales	24.1	26.4	9.4	[51.0]	51.8	6.9	[102.0]	103.5	2.2
SG&A expenses	57.0	67.3	18.2	[131.0]	134.7	14.3	[263.0]	270.5	9.6
SG&A expenses less R&D costs	41.8	47.2	13.1	[89.5]	92.2	8.8	[176.0]	181.0	3.1
R&D costs	15.2	20.1	32.2	[41.5]	42.5	28.1	[87.0]	89.5	25.5
Operating income	8.7	4.4	(48.9)		11.0	(7.9)		27.0	16.0
Ordinary income	9.6	4.7	(50.5)		11.0	(13.5)		26.5	13.6
Net income attributable to owners of the parent	5.8	5.9	3.2		8.0	(32.0)		18.0	16.5

Notes 1: Cost of sales includes provision for (reversal of) reserve for sales returns.

2: Change (%) represent ratio of changes from the corresponding period of the previous year.

3: The forecasts have been revised. Figures in parentheses [ ] are previously disclosed forecasts. Change (%) represents ratio of changes to the revised forecasts.

EBITDA (Billions of yen)	14.9	9.7	21.7	47.8
Earnings per share (yen)	14.49	14.95	20.14	45.31
Return on equity (ROE)	1.4%	1.3%	1.8%	3.9%

### 2. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2014 1Q	FY2015 1Q
Net cash provided by operating activities	8.8	5.4
Net cash provided by investing activities	8.6	25.8
Net cash used in financing activities	(5.7)	(6.4)
Cash and cash equivalents at the end of period	85.0	147.8

### 3. Currency Exchange Rates

(Billions of yen)

	2014 Apr.-Jun. Average rate	2015 Apr.-Jun. Average rate	2015 End of Jun.	FY2015 Assumed rate	Forex sensitivity FY2015 (Impact of yen weakness by 1yen/USD)	
Yen / USD	102.2	121.4	122.4	120.4	Net Sales	1.6
Yen / RMB	16.4	19.6	19.7	19.5	Operating Income	0.1

Note: Net sales and Operating income in FY2015 1Q increased by 7.5 billion yen and decreased by 0.2 billion yen respectively, compared to FY2014 1Q due to exchange rate fluctuation.

### 4. Capital Expenditures

(Billions of yen)

	FY2014 1Q	FY2015 1Q	Change	FY2015	
				Forecast	Change
Capital expenditures	1.9	1.0	(0.9)	11.5	1.8

Note: The amount of capital expenditures are for tangible fixed assets and software.

Major continuing capital expenditure projects for FY2015

Earthquake resistant renewal of research building No.2 in Osaka research center: ¥1.6billion  
(Total budget ¥1.6billion, plan to be completed in November 2015)

### 5. Depreciation and Amortization

(Billions of yen)

	FY2014 1Q	FY2015 1Q	Change	FY2015	
				Forecast	Change
Property, plant and equipment	1.9	1.9	0.1	7.4	(0.4)
Intangible assets	1.5	1.0	(0.5)	5.1	1.0
Goodwill	1.3	1.5	0.2	6.5	1.1

## II. Consolidated Statements of (Comprehensive) Income

### 1. Consolidated Statements of Income

(Billions of yen)

	FY2014 1Q (A)	FY2015 1Q (B)			
			(B)-(A)	Change (%)	
Net sales	89.7	98.1	8.4	9.3	<ul style="list-style-type: none"> <li>• Japan Segment +0.7</li> <li>• North America Segment +6.7</li> <li style="padding-left: 20px;">(FX rate impact +6.7)</li> <li>• China Segment +0.3</li> <li style="padding-left: 20px;">(FX rate impact +0.7)</li> </ul>
Overseas sales	42.5	49.8	7.3	17.1	
[% of net sales]	47.4%	50.7%			
Cost of sales	24.1	26.4	2.3	9.4	
[% of net sales]	26.8%	26.9%			
Gross profit	65.7	71.8	6.1	9.3	
SG&A expenses	57.0	67.3	10.4	18.2	
Labor costs	17.1	19.6	2.6	15.0	<ul style="list-style-type: none"> <li>• Due to increase in North America and weak yen</li> </ul>
Advertising and promotion costs	6.9	9.5	2.7	38.5	
Sales promotion costs	2.9	2.9	(0.0)	(0.4)	
Other costs	14.9	15.2	0.3	1.8	
SG&A expenses less R&D costs	41.8	47.2	5.5	13.1	
R&D costs	15.2	20.1	4.9	32.2	<ul style="list-style-type: none"> <li>• Due to increase in clinical development expense in North America and weak yen</li> </ul>
[% of net sales]	17.0%	20.5%			
Operating income	8.7	4.4	(4.3)	(48.9)	
Non-operating income	1.3	0.9	(0.5)		
Non-operating expenses	0.5	0.6	0.1		
Ordinary income	9.6	4.7	(4.8)	(50.5)	
Extraordinary income	1.7	6.0	4.3		
Gain on sales of investment securities	—	6.0	6.0		<ul style="list-style-type: none"> <li>• Sale of listed stock (North America)</li> </ul>
Compensation income for damage	1.7	—	(1.7)		
Extraordinary loss	0.1	0.2	0.0		
Impairment loss	—	0.2	0.2		<ul style="list-style-type: none"> <li>• Impairment of intangible asset (North America)</li> </ul>
Business structure improvement expenses	0.1	—	(0.1)		
Income before income taxes and minority interests	11.1	10.6	(0.6)	(5.0)	
Income taxes	5.4	4.6	(0.7)		
Net income	5.8	5.9	0.2	3.2	
Net income attributable to owners of the parent	5.8	5.9	0.2	3.2	

Notes 1: Cost of sales includes provision for (reversal of) reserve for sales returns.

2: Overseas sales includes exports of non-Pharmaceutical products.

### 2. Consolidated Statements of Comprehensive Income

(Billions of yen)

	FY2014 1Q	FY2015 1Q	
Net income	5.8	5.9	
Other comprehensive income	(4.2)	7.8	
Unrealized gains (losses) on available-for-sale securities, net of tax	(0.5)	1.7	
Deferred gains or losses on hedges	(0.0)	0.0	
Foreign currency translation adjustments	(3.8)	5.9	<ul style="list-style-type: none"> <li>Currency exchange rates : yen/\$</li> <li>3/2014 6/2014 3/2015 6/2015</li> <li>102.9 → 101.4 120.2 → 122.4</li> <li>(1.5) +2.3</li> </ul>
Remeasurements of defined benefit plans	0.1	0.1	
Comprehensive income	1.5	13.7	

## 3. Segment Information (FY2015 1Q)

(Billions of yen)

	Pharmaceuticals Business					Subtotal	Other Business *2	Total
	Japan	North America	China	Other Regions				
Net sales	38.2	42.3	4.6	2.8	87.8	10.3	98.1	
Sales to customers	38.2	42.3	4.6	2.8	87.8	10.3	98.1	
Intersegment	0.0	—	—	—	0.0	(0.0)	—	
Cost of sales	11.4	3.9	1.0	1.8	18.1	8.3	26.4	
Gross profit	26.8	38.4	3.6	1.0	69.7	2.0	71.8	
SG&A expenses less R&D costs	14.2	28.9	1.9	0.7	45.7	1.6	47.2	
Amortization included in above*1	—	1.9	—	—	1.9	—	1.9	
Income (loss) of segment	12.6	9.5	1.6	0.3	24.1	0.5	24.6	
R&D costs*3						19.9	0.2	20.1
Operating income						4.2	0.3	4.4

## Segment Information (FY2014 1Q)

(Billions of yen)

	Pharmaceuticals Business					Subtotal	Other Business *2	Total
	Japan	North America*1	China	Other Regions				
Net sales	37.5	35.6	4.2	2.5	79.8	9.9	89.7	
Sales to customers	37.5	35.6	4.2	2.5	79.8	9.9	89.7	
Intersegment	—	—	—	—	—	—	—	
Cost of sales	11.2	3.0	0.6	1.4	16.2	7.8	24.1	
Gross profit	26.3	32.6	3.6	1.0	63.6	2.1	65.7	
SG&A expenses less R&D costs	14.4	23.7	1.6	0.5	40.2	1.5	41.8	
Amortization included in above*1	—	2.6	—	—	2.6	—	2.6	
Income (loss) of segment	11.9	8.9	2.0	0.5	23.3	0.6	23.9	
R&D costs*3						15.0	0.2	15.2
Operating income						8.3	0.4	8.7

## Segment Information (FY2015 Forecasts)\*4

(Billions of yen)

	Pharmaceuticals Business					Subtotal	Other Business *2	Total
	Japan	North America*1	China	Other Regions				
Net sales	156.8	174.8	19.7	7.4	358.7	42.3	401.0	
Sales to customers	156.7	174.8	19.7	7.4	358.6	42.4	401.0	
Intersegment	0.1	—	—	—	0.1	(0.1)	—	
Cost of sales	48.0	13.9	3.9	4.3	70.1	33.4	103.5	
Gross profit	108.8	160.9	15.8	3.1	288.6	8.9	297.5	
SG&A expenses less R&D costs	58.1	105.1	8.7	2.5	174.4	6.6	181.0	
Amortization included in above*1	—	7.8	—	—	7.8	—	7.8	
Income (loss) of segment	50.7	55.8	7.1	0.6	114.2	2.3	116.5	
R&D costs*3						88.5	1.0	89.5
Operating income						25.7	1.3	27.0

Notes\*1: Amortization of goodwill and patent rights, etc.

\*2: Including the elimination of intersegment transaction.

\*3: R&amp;D costs are controlled globally and not allocated to each segment.

\*4: FY2015 forecasts have been revised.

4. Sales of Pharmaceuticals Business (Sales to customers)

(Billions of yen)

	FY2014 1Q (A)	FY2015 1Q (B)	(B)-(A)	Change (%)	FY2015 Apr.-Sep. (Forecast)	Progress vs. Apr.- Sep. forecast (%)	FY2015 (Forecast)
Japan	37.5	38.2	0.7	1.8	78.7	48.5	156.7
North America	35.6	42.3	6.7	18.8	[80.0] 84.0	52.9	[166.8] 174.8
China	4.2	4.6	0.3	8.1	[9.6] 10.1	47.6	[18.7] 19.7
Other Regions	2.5	2.8	0.3	12.4	3.6	76.5	7.4

Note: The forecasts of some products have been revised. Figures in parentheses [ ] are previously disclosed forecasts.

Progress % is against previous forecast.

5. Sales of Major Products

Japan(Strategic Products)

(Sales figures before reduction of rebates, Billions of yen)

Brand name (Generic name) Therapeutic indication	FY2014 1Q (A)	FY2015 1Q (B)	(B)-(A)	Change (%)	FY2015 Apr.-Sep. (Forecast)	Progress vs. Apr.- Sep. forecast (%)	FY2015 (Forecast)
AIMIX <sup>®</sup> (irbesartan/amlodipine) Therapeutic agent for hypertension (Launch: Dec. 2012)	2.6	3.5	0.9	35.8	7.8	44.8	17.5
AVAPRO <sup>®</sup> (irbesartan) Therapeutic agent for hypertension	2.8	2.7	(0.1)	(3.0)	5.8	46.4	11.5
LONASEN <sup>®</sup> (blonanserin) Atypical antipsychotic	2.3	3.1	0.8	32.4	6.4	48.3	13.0
TRETRIEF <sup>®</sup> (zonisamide) Parkinson's disease drug	2.4	3.3	0.8	35.3	7.0	46.6	15.2

Japan (Other Products)

SUREPOST <sup>®</sup> (repaglinide) Rapid-acting insulin secretagogue (Launch: May 2011)	0.5	0.8	0.4	75.1	1.7	48.1	3.7
AmBisome <sup>®</sup> (amphotericin B) Therapeutic agent for systemic fungal infection	0.9	1.0	0.1	8.8	2.4	41.2	4.9
REPLAGAL <sup>®</sup> (agalsidase alfa) Anderson-Fabry disease drug	2.4	2.8	0.4	15.3	5.4	51.3	11.0
METGLUCO <sup>®</sup> (metformin) Biguanide oral hypoglycemic	3.6	4.9	1.2	33.7	8.0	61.0	14.0
AMLODIN <sup>®</sup> (amlodipine) Therapeutic agent for hypertension and angina pectoris	5.1	4.2	(0.9)	(17.4)	8.9	47.4	17.0
GASMOTIN <sup>®</sup> (mosapride citrate) Gastroprokinetic	2.7	2.2	(0.5)	(18.0)	4.4	50.6	8.3
PRORENAL <sup>®</sup> (limaprost alfadex) Vasodilator	2.7	2.3	(0.4)	(13.6)	4.7	49.1	9.1
MEROPEN <sup>®</sup> (meropenem) Carbapenem antibiotic	2.0	1.6	(0.4)	(18.9)	3.6	45.7	6.8
EBASTEL <sup>®</sup> (ebastine) Antiallergic	0.9	0.6	(0.3)	(29.2)	1.4	45.9	3.2

## North America

(Billions of yen)

Brand name (Generic name) Therapeutic indication	FY2014 1Q (A)	FY2015 1Q (B)	(B)-(A)	Change (%)	FY2015 Apr.-Sep. (Forecast)	Progress vs. Apr.-Sep. forecast (%)	FY2015 (Forecast)
LATUDA <sup>®</sup> (lurasidone) Atypical antipsychotic (Launch: Feb. 2011)	18.4	26.5	8.1	44.0	[53.9] 56.5	49.1	[115.0] 120.4
APTIOM <sup>®</sup> (eslicarbazepine acetate) Antiepileptic (Launch: Apr. 2014)	9.0	1.5	0.7	78.5	[2.2] 2.8	69.0	[6.2] 7.0
BROVANA <sup>®</sup> (arformoterol tartrate) Long-acting beta-agonist	4.7	7.0	2.3	48.0	[11.8] 12.4	59.5	[25.1] 26.2
Ciclesonide * Inhaled corticosteroid / corticosteroid nasal spray	1.6	2.1	0.5	28.5	[3.1] 3.2	66.3	[6.0] 6.3
XOPENEX <sup>®</sup> (levalbuterol HCl) Short-acting beta-agonist	2.4	1.6	(0.8)	(33.7)	[2.1] 2.2	76.7	[2.5] 2.6
LUNESTA <sup>®</sup> (eszopiclone) Sedative hypnotic	4.7	1.3	(3.4)	(72.6)	[2.1] 2.2	62.1	[3.7] 3.9
Industrial property revenues	1.3	1.1	(0.1)	(10.8)	[2.2] 2.3	51.5	[4.4] 4.6

## China

(Billions of yen)

Brand name (Generic name)	FY2014 1Q (A)	FY2015 1Q (B)	(B)-(A)	Change (%)	FY2015 Apr.-Sep. (Forecast)	Progress vs. Apr.-Sep. forecast (%)	FY2015 (Forecast)
MEROPEN <sup>®</sup> (meropenem)	3.5	3.8	0.3	7.8	[7.9] 8.4	47.7	[15.3] 16.1

## Other Regions

(Billions of yen)

Brand name (Generic name)	FY2014 1Q (A)	FY2015 1Q (B)	(B)-(A)	Change (%)	FY2015 Apr.-Sep. (Forecast)	Progress vs. Apr.-Sep. forecast (%)	FY2015 (Forecast)
MEROPEN <sup>®</sup> (meropenem) (Export)	1.0	1.7	0.7	76.1	2.0	85.3	4.3
Industrial property revenues	0.1	0.0	(0.1)	(84.7)	0.3	5.5	1.0

## (Reference) Sales of Products in North America Segment (based on local currency)

(Millions of dollars)

Brand name (Generic name)	FY2014 1Q (A)	FY2015 1Q (B)	(B)-(A)	Change (%)	FY2015 Apr.-Sep. (Forecast)	Progress vs. Apr.-Sep. forecast (%)	FY2015 (Forecast)
LATUDA <sup>®</sup> (lurasidone)	180	218	38	21.2	469	46.5	1,000
APTIOM <sup>®</sup> (eslicarbazepine acetate)	8	13	4	50.2	[19] 23	65.8	[54] 58
BROVANA <sup>®</sup> (arformoterol tartrate)	46	58	11	24.5	103	56.1	218
Ciclesonide *	16	17	1	8.1	26	65.1	52
XOPENEX <sup>®</sup> (levalbuterol HCl)	24	13	(11)	(44.2)	18	73.6	22
LUNESTA <sup>®</sup> (eszopiclone)	46	11	(36)	(76.9)	18	65.1	32
Industrial property revenues	12	9	(3)	(25.0)	19	49.1	38

\* Total of 3 ciclesonide products (ALVESCO<sup>®</sup>, OMNARIS<sup>®</sup>, ZETONNA<sup>®</sup>)

Note: The forecasts of some products have been revised. Figures in parentheses [ ] are previously disclosed forecasts.

Progress rate is against previous forecast.

### III. Consolidated Balance Sheets

#### ASSETS

(Billions of yen)

	As of Mar. 31, 2015 (A)	As of Jun. 30, 2015 (B)	(B)-(A)
[ Assets ]	711.6	727.3	15.7
Current assets:	401.7	417.0	15.3
Cash and time deposits	30.6	21.5	(9.0)
Notes and accounts receivable	103.1	106.9	3.8
Marketable securities	111.3	130.9	19.6
Inventories	62.4	63.8	1.5
Deferred tax assets	38.9	42.9	4.1
Short-term loans receivable	49.1	42.9	(6.2)
Others	6.6	8.0	1.4
Allowance for doubtful receivables	(0.1)	(0.0)	0.1
Fixed assets:	309.9	310.4	0.5
Property, plant and equipment:	65.2	64.1	(1.0)
Buildings and structures	41.4	40.9	(0.4)
Machinery, equipment and carriers	9.1	8.9	(0.1)
Land	6.3	6.3	0.0
Construction in progress	1.2	1.1	(0.1)
Others	7.2	6.8	(0.4)
Intangible assets:	173.9	174.4	0.5
Goodwill	88.1	88.2	0.1
In-process research & development	64.5	65.4	0.9
Others	21.3	20.8	(0.5)
Investments and other assets:	70.9	71.9	1.0
Investment securities	58.2	61.0	2.8
Asset for retirement benefit	1.9	2.0	0.1
Deferred tax assets	4.8	3.3	(1.4)
Others	6.0	5.6	(0.4)
Allowance for doubtful receivables	(0.0)	(0.0)	0.0
Total assets	711.6	727.3	15.7

Increase in bonds and  
certificate of deposit

Amortization -1.5  
Exchange rate +1.7

Exchange rate +1.2  
Impairment -0.2

Accounts receivable turnover period  
(in months)

3.33      3.27

## LIABILITIES AND NET ASSETS

(Billions of yen)

	As of Mar. 31, 2015 (A)	As of Jun. 30, 2015 (B)	(B)-(A)	
[ Liabilities ]	260.6	269.1	8.5	
Current liabilities:	156.8	162.1	5.2	
Notes and accounts payable	12.5	13.8	1.3	
Current portion of bonds payable	30.0	30.0	—	
Current portion of long-term loans payable	6.5	3.7	(2.9)	Total interest-bearing debt 86.5→83.7
Income taxes payable	3.3	7.1	3.9	
Reserve for bonuses	9.4	5.8	(3.7)	
Reserve for sales returns	8.6	8.9	0.3	
Reserve for sales rebates	36.4	43.8	7.5	Increase in LATUDA® sales and FX impact
Accounts payable-other	35.3	30.2	(5.1)	
Others	14.9	18.8	3.9	
Long-term liabilities:	103.7	107.0	3.3	
Bonds payable	30.0	30.0	—	
Long-term loans payable	20.0	20.0	—	
Deferred tax liabilities	17.4	18.9	1.5	
Liability for retirement benefit	15.3	15.4	0.1	
Others	21.1	22.7	1.6	
[ Net assets ]	451.0	458.2	7.2	
Shareholders' equity:	364.3	363.8	(0.5)	
Common stock	22.4	22.4	—	
Capital surplus	15.9	15.9	—	
Retained earnings	326.7	326.2	(0.5)	
Treasury stock	(0.7)	(0.7)	(0.0)	
Accumulated other comprehensive income (loss):	86.7	94.4	7.7	
Unrealized gains on available-for-sale securities, net of tax	23.1	24.8	1.7	
Deferred gains or losses on hedges	0.0	0.0	0.0	
Foreign currency translation adjustments	68.2	73.9	5.8	Currency exchange rates: yen/\$ 03/2015 03/2016 120.2 → 122.4
Remeasurement of defined benefit plans	(4.5)	(4.4)	0.1	
Total liabilities and net assets	711.6	727.3	15.7	



#### IV. Quarterly Business Results

(Billions of yen)

	FY2014				FY2015
	1Q	2Q	3Q	4Q	1Q
Net sales	89.7	88.5	100.8	92.2	98.1
Cost of sales	24.1	24.4	26.6	26.1	26.4
SG&A expenses	57.0	60.9	63.3	65.6	67.3
SG&A expenses less R&D costs	41.8	43.0	45.3	45.5	47.2
R&D costs	15.2	18.0	18.0	20.1	20.1
Operating income (loss)	8.7	3.3	10.9	0.5	4.4
Non-operating income	1.3	1.0	0.5	1.4	0.9
Non-operating expenses	0.5	1.1	1.6	1.0	0.6
Ordinary income (loss)	9.6	3.2	9.8	0.8	4.7
Extraordinary income	1.7	8.3	7.7	0.0	6.0
Extraordinary loss	0.1	0.5	5.3	1.4	0.2
Income (Loss) before income taxes and minority interests	11.1	10.9	12.2	(0.5)	10.6
Net income (loss) attributable to owners of the parent	5.8	6.0	7.2	(3.5)	5.9

Note: Cost of sales includes provision for (reversal of) reserve for sales returns.

#### V. Major Consolidated Subsidiaries (As of June 30, 2015)

Domestic	DSP Gokyo Food & Chemical Co., Ltd.	DS Pharma Animal Health Co., Ltd.	DS Pharma Biomedical Co., Ltd.
Establishment	October 1947	July 2010	June 1998
Ownership	100%	100%	100%
Number of employees	163	103	64
Businesses	Manufacturing and sales of food ingredients, food additives, chemical product materials, etc.	Manufacturing, and sales of veterinary medicines, etc.	Manufacturing and sales of diagnostics, etc.
Overseas	Sunovion Pharmaceuticals Inc.	Boston Biomedical, Inc.	Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
Establishment	January 1984	November 2006	December 2003
Ownership	100%	100%	100%
Number of employees	1599	89	711
Businesses	Manufacturing and sales of pharmaceuticals	R&D in the oncology area	Manufacturing and sales of pharmaceuticals

(Reference) Number of employees and MRs

	As of Mar. 31, 2014	As of Mar. 31, 2015	As of Jun. 30, 2015
consolidated	7,015	6,868	6,872
non-consolidated	4,331	4,126	4,133
MRs Japan			
(excluding managers)	1,400	1,350	1,350
(including managers)	1,600	1,530	1,530
MRs U.S.			
(excluding managers)	710	700	680
(including managers)	810	800	780
MRs China			
(excluding managers)	390	370	350
(including managers)	480	470	450

## VI. Development Pipeline (As of July 29, 2015)

### ■ Submitted stage

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Submitted	Amrubicin hydrochloride Injection	amrubicin hydrochloride	Small cell lung cancer	In-house	China	Submitted in August 2012 Brand name in Japan: CALSED®
	Blonanserin Oral	blonanserin	Schizophrenia	In-house	China	Submitted in September 2013 Brand name in Japan: LONASEN®
	APTIOM® Oral	eslicarbazepine acetate	(New indication) Epilepsy (Monotherapy)	BIAL	U.S. , Canada	Submitted in October 2014 Approved indication: Epilepsy (Adjunctive therapy)

### ■ Phase III stage (1/2)

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase III	AS-3201 Oral	ranirestat	Diabetic neuropathy	In-house	Japan	
	SM-13496 Oral	lurasidone hydrochloride	Schizophrenia	In-house	Japan	Approved in the U.S., Canada, Europe and Australia (A Phase III study completed, development strategy under consideration)
			Bipolar I depression			Approved in the U.S. and Canada
			Bipolar maintenance			
			Schizophrenia		China	Approved in the U.S., Canada, Europe and Australia
LATUDA® Oral		(New indication) Bipolar maintenance		U.S., Europe, etc.		

■ Phase III stage (2/2)

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase III	BBI608 Oral	TBD	Colorectal cancer (Monotherapy)	In-house	U.S., Canada, Japan, etc.	Global clinical trial Further enrollment of new patients was stopped and all patients discontinued study therapy in May 2014
			Gastric and Gastro-esopha geal junction adenocarcinoma (Combination therapy)		U.S., Canada, Japan, etc.	Global clinical trial
	SEP-225289 Oral	dasotraline	Adult attention-deficit hyperactivity disorder (ADHD)	In-house	U.S.	
	SUN-101 Inhalant	glycopyrrolate bromide	Chronic obstructive pulmonary disease (COPD)	In-house	U.S.	From the former Elevation Pharmaceuticals
	LONASEN® Oral	blonanserin	(Addition of pediatric usage) Schizophrenia	In-house	Japan	Joint development with Nitto Denko Approved formulation: Oral
	LONASEN® Transdermal Patch		(New formulation – Transdermal patch) Schizophrenia			
TRERIEF® Oral	zonisamide	(New indication) Parkinsonism in Dementia with Lewy Bodies (DLB)	In-house	Japan		

■ Phase II / III stage

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase II/III	EPI-743 Oral	vatiquinone	Leigh syndrome	Edison Pharma- ceuticals	Japan	A Phase II / III study completed, development strategy under consideration
	SEP-225289 Oral	dasotraline	Pediatric attention-deficit hyperactivity disorder (ADHD)	In-house	U.S.	
Binge eating disorder (BED)						

■ Phase II stage

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase II	BBI608 Oral	TBD	Colorectal cancer (Combination therapy)	In-house	U.S., Canada	
	DSP-1747 Oral	obeticholic acid	Nonalcoholic steatohepatitis (NASH)	Intercept Pharmaceuticals	Japan	
	DSP-6952 Oral	TBD	IBS with constipation, Chronic idiopathic constipation	In-house	Japan	
	BBI503 Oral	TBD	Renal cell carcinoma, Urothelial carcinoma (Monotherapy)	In-house	Canada	
			Hepatocellular carcinoma, Cholangio carcinoma (Monotherapy)			
			Gastrointestinal stromal tumor (Monotherapy)			
			Ovarian cancer (Monotherapy)		U.S.	
	SB623 Injection	TBD	Chronic Stroke	SanBio	U.S.	Joint development with SanBio
EPI-589 Oral	TBD	Parkinson disease	Edison Pharmaceuticals	U.S.	Conducting by Edison Pharmaceuticals	
		Amyotrophic lateral sclerosis (ALS)				

■ Phase I / II stage

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase I/II	BBI608 Oral	TBD	Solid tumors (Combination therapy)	In-house	U.S., Canada	Phase II : Ovarian cancer, Breast cancer, Non-small cell lung cancer, Melanoma, etc.
			Malignant pleural mesothelioma (Combination therapy)		Japan	Phase II
			Hepatocellular carcinoma (Combination therapy)		U.S.	
			Glioblastoma (Combination therapy)		Canada	
			Solid tumors (Combination therapy)		U.S.	
	BBI503 Oral	TBD	Solid tumors (Monotherapy)	In-house	U.S., Canada	Phase II : Colorectal cancer, Head and Neck cancer, Ovarian cancer, etc.
			Hepatocellular carcinoma (Combination therapy)		U.S.	
			Solid tumors (Combination therapy)			
	WT4869 Injection	TBD	Myelodysplastic syndromes	Joint research with Chugai Pharma- ceutical	Japan	Independent development after April 2013
	DSP-7888 Injection	TBD	Myelodysplastic syndromes	In-house	Japan	

■ Phase I stage (1/2)

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase I	WT4869 Injection	TBD	Solid tumors	Joint research with Chugai Pharma- ceutical	Japan	Independent development after April 2013
	WT2725 Injection	TBD	Solid tumors, Hematologic malignancies	Joint research with Chugai Pharma- ceutical	U.S.	Independent development after April 2013
			Solid tumors		Japan	
	DSP-2230 Oral	TBD	Neuropathic pain	In-house	U.K., U.S.	
	SEP-363856 Oral	TBD	Schizophrenia	In-house	U.S.	
	BBI608 Oral	TBD	Gastrointestinal cancer (Combination therapy)	In-house	U.S., Canada	
			Pancreatic cancer (Combination therapy)		U.S.	
			Hematologic malignancies (Monotherapy / Combination therapy)			
			Hepatocellular carcinoma (Combination therapy)		Japan	
	DSP-3748 Oral	TBD	Cognitive impairment associated with schizophrenia	In-house	U.S.	
BBI503 Oral	TBD	Solid tumors (Monotherapy), Hepatocellular carcinoma (Combination therapy)	In-house	Japan		

■ Phase I stage (2/2)

Stage	Brand name/ Product code Formulation	Generic name	Proposed indication	Origin	Country/ Area	Remarks
Phase I	BBI608+BBI503 Oral	-	Solid tumors (Combination therapy)	In-house	U.S.	
	DSP-7888 Injection	TBD	Solid tumors, Hematologic malignancies	In-house	U.S.	

[Main revisions since the announcement of May 2015]

EPI-743 (Leigh syndrome)	Completed Phase II / III study in Japan. The future development strategy in Japan is under consideration.
SEP-225289 (BED)	Newly added in Phase II / III in the U.S.
EPI-589 (Parkinson disease, ALS)	Newly added in Phase II in the U.S.
BBI608 (Malignant pleural mesothelioma / Combination)	Started Phase II of Phase I / II in Japan
BBI608 (Solid tumors / Combination)	Newly added in Phase I / II in the U.S.
BBI503 (Solid tumors / Combination)	Newly added in Phase I / II in the U.S.
DSP-7888 (Solid tumors, Hematologic malignancies)	Newly added in Phase I in the U.S.

### Major Products under Development by Licensees

Generic / Product code (Brand name in JPN)	Proposed indications	Status of development
vosaroxin AG-7352	Cancer	Out-licensed to Sunesis Pharmaceuticals Inc. for the worldwide territory in October 2003. Multinational Phase III study completed by Sunesis (Sunesis' product code: SNS-595) in October 2014.
amrubicin hydrochloride (CALSED®)	Small cell lung cancer	Out-licensed to Celgene (former Pharmion) for the U.S. and European territories in June 2005. Phase III study completed in the U.S. and Europe by Celgene.
droxidopa (DOPS®)	Neurogenic orthostatic hypotension, Intradialytic hypotension, Fibromyalgia	Out-licensed to Lundbeck (former Chelsea Therapeutics) for the worldwide territory, excluding Japan, China, Korea and Taiwan in May 2006. Lundbeck obtained the approval for neurogenic orthostatic hypotension in the U.S. in February 2014, and launched in the U.S. in September 2014 (Lundbeck's brand name: NORTHERA™). Phase II study of fibromyalgia and phase II study of intradialytic hypotension completed by Lundbeck.
lurasidone hydrochloride SM-13496	Schizophrenia Bipolar disorder	Entered into a license agreement with Takeda Pharmaceutical for co-development and exclusive commercialization for the European territory, excluding the U.K. in March 2011. Takeda submitted an MAA in Europe for schizophrenia in September 2012. Takeda obtained the approval for schizophrenia in Switzerland in August 2013. Out-licensed to Standard Chem. & Pharm. for Taiwan in August 2013, and submitted for schizophrenia in Taiwan in October 2013. Out-licensed to Daiichi Sankyo for rights or option rights in four South American countries to commercialize in January 2014. Takeda obtained the approval in Europe for schizophrenia in March 2014. Takeda submitted an NDA in Russia and Turkey for schizophrenia in December 2014. Daiichi Sankyo submitted an NDA in Venezuela for schizophrenia in December 2014. Entered into a distribution, marketing and sales agreement with DKSH Thailand for Thailand, Hong Kong and Singapore in January 2015. DKSH submitted an NDA for schizophrenia in Thailand in November 2014, in Hong Kong in December 2014, in Singapore in April 2015. The license agreement with Takeda for the joint development and exclusive commercialization in Europe will be terminated, and discussions for establishing a transition plan for the transfer of the rights and activities was started in May 2015.
SMP-986	Nocturia	Out-licensed to Nippon Shinyaku for rights in Japan to develop and commercialize in March 2013. Phase II study completed in Japan by Nippon Shinyaku. (Nippon Shinyaku's product code: NS-986).

[Main revisions since the announcement of May 2015]

None



## VII. Profile of Major Products under Development (As of July 29, 2015)

### APTIOM<sup>®</sup> (eslicarbazepine acetate) Epilepsy

- In-licensed from BIAL Portela & C<sup>a</sup>, S.A.
- A novel voltage-gated sodium channel blocker. It is taken once daily and can be taken whole or crushed, with or without food. APTIOM<sup>®</sup> is not classified as a controlled substance by the FDA.
- Sunovion obtained the approval of APTIOM<sup>®</sup> for use as adjunctive treatment of partial-onset seizures in the U.S. in November 2013 and launched in the U.S. in April 2014. The approval is based on three global studies which were jointly performed with BIAL. These were randomized, double-blind, placebo-controlled studies, which included more than 1,400 people living with partial-onset seizures inadequately controlled by one to three concomitant AEDs. APTIOM<sup>™</sup> was approved for use as adjunctive treatment of partial-onset seizures in Canada in July 2014.
- Development stage: Epilepsy (monotherapy): Submitted in the U.S. and Canada in October 2014

### LATUDA<sup>®</sup> (lurasidone hydrochloride) Atypical antipsychotic

- Developed in-house
- LATUDA<sup>®</sup> (lurasidone hydrochloride) is an atypical antipsychotic agent that is believed to have an affinity for dopamine D<sub>2</sub>, serotonin 5-HT<sub>2A</sub> and serotonin 5-HT<sub>7</sub> receptors where it has antagonist effects. In addition, LATUDA is a partial agonist at the serotonin 5-HT<sub>1A</sub> receptor and has no appreciable affinity for histamine or muscarinic receptors.
- In the clinical studies supporting the U.S. FDA approval, the efficacy of LATUDA for the treatment of schizophrenia was established in four, short-term (6-week), placebo-controlled clinical studies in adult patients. In these studies, LATUDA demonstrated significantly greater improvement versus placebo. A total of five short-term placebo-controlled clinical studies contributed to the understanding of the tolerability and safety profile of LATUDA. LATUDA was approved for the treatment of schizophrenia by the U.S. FDA in October 2010, and launched by Sunovion in the U.S. in February 2011. For the treatment of schizophrenia, LATUDA was approved in Canada in June 2012, in Switzerland in August 2013, in Europe and Australia in March 2014.  
For the treatment of bipolar I depression, LATUDA was approved as the first atypical antipsychotic indicated for the treatment of bipolar I depression as a monotherapy and as an adjunctive therapy to lithium or valproate by the U.S. FDA in June 2013. In addition, LATUDA was approved in Canada in March 2014.
- Development stage:

Stage	Proposed indication	Country, Area	Partners
Submitted	Schizophrenia	Russia, Turkey	Takeda Pharmaceutical <sup>*1</sup>
	Schizophrenia	Taiwan	Standard Chem. & Pharm.
	Schizophrenia	Thailand, Hong Kong, Singapore	DKSH
	Schizophrenia	Venezuela	Daiichi Sankyo
Phase III	Schizophrenia	Japan <sup>*2</sup> , China	In-house
	Bipolar I depression, Bipolar maintenance	Japan	In-house
	Bipolar I depression	Europe	Takeda Pharmaceutical <sup>*1</sup>
	Bipolar maintenance	U.S., Europe, etc.	In-house

\*1 The license agreement with Takeda for the joint development and exclusive commercialization in Europe will be terminated, and discussions on establishing a transition plan for the transfer of the rights and activities were started in May 2015.

\*2 A Phase III study completed, development strategy under consideration

**ranirestat (AS-3201)                      Diabetic neuropathy**

- Developed in-house
- AS-3201 is expected to alleviate diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This compound has a stronger inhibitory effect and is longer-acting compared to other drugs in this therapeutic area. Clinical studies have shown AS-3201 to have good penetration into nerve tissues, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose. Based on the results of clinical studies, AS-3201 is expected to show improvement of neuronal function and symptoms related to diabetic neuropathy.
- Development stage: Phase III in Japan

**BBI608                                      Anticancer drug**

- Developed in-house (Boston Biomedical, Inc.)
- BBI608 is an orally administered small molecule investigational agent that targets Stat3, leading to inhibition of the critical genes for maintaining cancer stemness. By targeting cancer stem cell pathways, it may provide a new therapeutic option against cancer challenges such as treatment resistance, recurrence and metastasis.
- BBI608 has been shown to inhibit the Stat3 pathways, Nanog pathways and  $\beta$ -catenin pathways in the pre-clinical study.
- Development stage:

Stage	Proposed indication	Country, Area	Combination products	Study number
Phase III	Colorectal cancer (monotherapy) <sup>*1</sup>	U.S., Canada, Japan, etc.	-	CO.23
	Gastric and Gastro-esophageal junction adenocarcinoma (combination therapy)	U.S., Canada, Japan, etc.	paclitaxel	336 (BRIGHTER)
Phase II	Colorectal cancer (combination therapy)	U.S., Canada	cetuximab, panitumumab or capecitabine	224
Phase I / II	Solid tumors <sup>*2</sup> (combination therapy)	U.S., Canada	Paclitaxel	201
	Malignant pleural mesothelioma (combination therapy)	Japan	cisplatin and pemetrexed	D8807005
	Hepatocellular carcinoma (combination therapy)	U.S.	Sorafenib	HCC-103
	Glioblastoma (combination therapy)	Canada	Temozolomide	251
	Solid tumors (combination therapy)	U.S.	ipilimumab, pembrolizumab or nivolumab	201CIT
Phase I	Gastrointestinal cancer (combination therapy)	U.S., Canada	FOLFOX <sup>3</sup> , FOLFOX <sup>3</sup> and bevacizumab, CAPOX <sup>3</sup> , FOLFIRI <sup>3</sup> , FOLFIRI <sup>3</sup> and bevacizumab, or regorafenib	246
	Pancreatic cancer (combination therapy)	U.S.	gemcitabine and nab-paclitaxel	118
	Hematologic malignancies (monotherapy / combination therapy)	U.S.	dexamethasone	103HEME
	Hepatocellular carcinoma (combination therapy)	Japan	sorafenib	D8808001
	Solid tumors (combination therapy)	U.S.	BBI503	401-101

\*1 Further enrollment of new patients was stopped and all patients discontinued study therapy in May 2014.

\*2 Phase II : Ovarian cancer, Breast cancer, Non-small cell lung cancer, Melanoma, etc.

\*3 FOLFOX: Combination therapy with fluorouracil, leucovorin, oxaliplatin

CAPOX: Combination therapy with capecitabine, oxaliplatin

FOLFIRI: Combination therapy with fluorouracil, leucovorin, irinotecan

**dasotraline (SEP-225289) Attention-deficit hyperactivity disorder (ADHD), Binge eating disorder (BED)**

- Developed in-house (Sunovion Pharmaceuticals Inc.)
- SEP-225289 is a DNRI that inhibits the reuptake of dopamine and norepinephrine. SEP-225289 is being developed as a once daily long-acting treatment. Due to its ability to maintain a stable concentration in blood levels all day, it is expected to be effective over the course of the day.
- Development stage:  
Adult attention-deficit hyperactivity disorder (ADHD): Phase III in the U.S.  
Pediatric attention-deficit hyperactivity disorder (ADHD): Phase II/III in the U.S.  
Binge eating disorder (BED): Phase II/III in the U.S.

**glycopyrrolate bromide (SUN-101) Chronic obstructive pulmonary disease (COPD)**

- Developed in-house (Sunovion Pharmaceuticals Inc.)
- SUN-101 is an inhalation solution of a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the Pari eFlow<sup>®</sup> nebulizer system, which is portable and able to deliver medication in approximately two minutes utilizing a vibrating membrane. Currently, there are no LAMAs delivered via nebulizer that are approved by the U.S. Food and Drug Administration (FDA). SUN-101 is a nebulizer delivered LAMA for COPD that the most advanced development stage.
- Development stage: Phase III in the U.S.

**vatiquinone (EPI-743) Mitochondrial disease**

- In-licensed from Edison Pharmaceuticals
- EPI-743 is for synchronizing energy generation in the mitochondria with the counterbalancing of redox stress. It is expected to be the world's first treatment for mitochondrial diseases beginning with Leigh syndrome.
- Development stage:  
A Phase II/III study for Leigh syndrome in Japan completed, development strategy under consideration

**obeticholic acid (DSP-1747) Nonalcoholic steatohepatitis (NASH), Primary biliary cirrhosis (PBC)**

- In-licensed from Intercept Pharmaceuticals Inc. (Intercept's product code: INT-747)
- DSP-1747 is an agonist for farnesoid X receptor (FXR) whose ligand is the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist. The compound is expected to be effective for hepatic dysfunction and hepatic fibrosis associated with an increase of bile acid in the liver.
- Development stage: Phase II in Japan for NASH. Phase II for PBC is under consideration.

**DSP-6952 IBS with constipation, Chronic idiopathic constipation**

- Developed in-house
- DSP-6952 is a high-affinity serotonin-4 receptor partial agonist with enterokinetic effect. DSP-6952 is expected to be effective for IBS with constipation and chronic idiopathic constipation by increasing complete spontaneous bowel movement.
- Development stage: Phase II in Japan

**BBI503                      Anticancer drug**

- Developed in-house (Boston Biomedical, Inc.)
- BBI503 is an orally administered small-molecule investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases. By targeting cancer stem cell pathways, it may provide a new therapeutic option against cancer challenges such as treatment resistance, recurrence and metastasis.
- BBI503 has been shown to inhibit multi-kinase in pre-clinical study.
- Development stage:

Stage	Proposed indication	Country, Area	Combination products	Study number
Phase II	Renal cell carcinoma, Urothelial carcinoma (monotherapy)	Canada	-	205a
	Hepatocellular carcinoma, Cholangiocarcinoma (monotherapy)	Canada	-	205b
	Gastrointestinal stromal tumor (monotherapy)	Canada	-	205c
	Ovarian cancer (monotherapy)	U.S.	-	205GYN-M
Phase I / II	Solid tumors* (monotherapy)	U.S., Canada	-	101
	Hepatocellular carcinoma (combination therapy)	U.S.	sorafenib	HCC-103
	Solid tumors (combination therapy)	U.S.	capecitabine, doxorubicin, nivolumab, pembrolizumab, paclitaxel or sunitinib	201
Phase I	Solid tumors (monotherapy), Hepatocellular carcinoma (combination therapy)	Japan	sorafenib	DA101003
	Solid tumors (combination therapy)	U.S.	BB1608	401-101

\* Phase II : Colorectal cancer, Head and Neck cancer, Ovarian cancer, etc.

**SB623                      Stroke**

- In-licensed from SanBio and joint development with SanBio
- SB623 is an allogeneic cell product, derived from bone marrow stromal cells isolated from healthy donors. Unlike autologous cell therapy, which requires individualized cell preparation at the health care institution, SB623 production can be scaled from a single donor's cells, enabling delivery of uniform-quality products to a large number of stroke patients. In preclinical and clinical studies to date, SB623 has shown beneficial results for stroke disability with no serious adverse events which are associated with SB623.
- Development stage: Phase II in the U.S.

**EPI-589                      Neurodegenerative diseases**

- In-licensed from Edison Pharmaceuticals
- EPI-589 is for synchronizing energy generation in the mitochondria with the counterbalancing of redox stress. It is expected to be developed for neurodegenerative indications arising through redox stress.
- Development stage:  
Parkinson disease: Phase II in the U.S. by Edison Pharmaceuticals  
Amyotrophic lateral sclerosis (ALS): Phase II in the U.S. by Edison Pharmaceuticals

**WT4869                    Anticancer drug**

- Developed in-house (Joint research with Chugai Pharmaceutical)
- WT4869 is a therapeutic cancer peptide vaccine candidate derived from Wilms' tumor gene 1 (WT1) protein. WT4869 is expected to treat various types of hematologic malignancies and solid tumors that express WT1, by inducing WT1-specific cytotoxic T-lymphocytes that attack WT1-expressing cancerous cells.
- Development stage:  
Myelodysplastic syndromes (MDS): Phase I/II in Japan  
Solid tumors: Phase I in Japan

**DSP-7888                    Anticancer drug**

- Developed in-house
- DSP-7888 is a therapeutic cancer peptide vaccine candidate derived from Wilms' tumor gene 1 (WT1) protein. DSP-7888 is a novel peptide vaccine candidate containing peptides that induce WT1-specific cytotoxic T lymphocytes (CTLs) and helper T cells. DSP-7888 is expected to become treatment options for patients with various types of hematologic malignancies and solid tumors that express WT1, by inducing of WT1-specific CTLs that attack WT1-expressing cancers cells. By adding a helper T cell-inducing peptide, stronger efficacy is expected than for a CTL-inducing peptide alone. DSP-7888 is expected to be an option for a wide range of patients.
- Development stage:  
Myelodysplastic syndromes (MDS): Phase I/II in Japan  
Solid tumors, Hematologic malignancies : Phase I in the U.S.

**DSP-2230                    Neuropathic pain**

- Developed in-house
- DSP-2230 is a novel compound that selectively inhibits voltage-gated sodium channels Nav1.7 and Nav1.8 with higher potencies than those against the other sodium channel subtypes studied. In addition, DSP-2230 has demonstrated antiallodynic effects in animal models of neuropathic pain that have been shown to be predictive of efficacy in humans. Due to its novel mechanism, DSP-2230 is expected not to produce CV or CNS side effects, which are present with the current drugs, such as non-selective sodium channel blockers and anti-epilepsy medicines.
- Development stage: Phase I in the U.K. and the U.S.

**WT2725                    Anticancer drug**

- Developed in-house (Joint research with Chugai Pharmaceutical)
- WT2725 is a therapeutic cancer peptide vaccine candidate derived from Wilms' tumor gene 1 (WT1) protein. WT2725 is expected to treat various types of hematologic malignancies and solid tumors that express WT1, by inducing WT1-specific cytotoxic T-lymphocytes that attack WT1-expressing cancerous cells.
- Development stage:  
Solid tumors, Hematologic malignancies: Phase I in the U.S.  
Solid tumors: Phase I in Japan

**SEP-363856      Schizophrenia**

- Developed in-house (Sunovion Pharmaceuticals Inc.)
- SEP-363856 is an antipsychotic with a novel mechanism of action. Compared to existing antipsychotics that are effective for positive symptoms of schizophrenia, the preclinical model also shows efficacy for the negative symptoms. Even in combination treatment with atypical antipsychotics, extrapyramidal side effects were not observed. High efficacy and improved QOL are expected for the treatment for schizophrenia.
- Development stage: Phase I in the U.S.

**DSP-3748      Cognitive impairment associated with schizophrenia (CIAS)**

- Developed in-house
- DSP-3748 is a positive allosteric modulator (PAM) of  $\alpha 7$ -type nicotinic acetylcholine receptor ( $\alpha 7$ nAChR). DSP-3748 is expected to treat patients with cognitive impairment associated with schizophrenia (CIAS) by enhancing the ACh transmission via  $\alpha 7$ nAChR. DSP-3748 is expected to cause less desensitization compared with a conventional agonist.
- Development stage: Phase I in the U.S.